Ross Moat Sells 64,035 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) insider Ross Moat sold 64,035 shares of Kiniksa Pharmaceuticals stock in a transaction on Tuesday, April 29th. The shares were sold at an average price of $25.21, for a total value of $1,614,322.35. Following the completion of the sale, the insider now directly owns 9,415 shares of the company’s stock, valued at approximately $237,352.15. This represents a 87.18 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Ross Moat also recently made the following trade(s):

• On Thursday, May 1st, Ross Moat sold 23,234 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $28.02, for a total value of $651,016.68.
• On Monday, April 21st, Ross Moat sold 18,259 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $20.29, for a total transaction of $370,475.11.

Kiniksa Pharmaceuticals Trading Down 0.3 %

NASDAQ:KNSA opened at $27.65 on Friday. The firm’s fifty day simple moving average is $21.77 and its 200 day simple moving average is $21.36. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $17.38 and a twelve month high of $28.15. The firm has a market capitalization of $2.01 billion, a price-to-earnings ratio of -197.49 and a beta of 0.31.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company had revenue of $137.79 million during the quarter, compared to the consensus estimate of $128.35 million. During the same quarter in the prior year, the business earned ($0.25) earnings per share. The company’s revenue was up 72.5% compared to the same quarter last year. On average, analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

KNSA has been the subject of several research analyst reports. Jefferies Financial Group upped their price target on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday. Citigroup began coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a “buy” rating and a $40.00 price objective for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals currently has an average rating of “Buy” and an average price target of $38.00.

Institutional Trading of Kiniksa Pharmaceuticals

Large investors have recently bought and sold shares of the company. GAMMA Investing LLC boosted its stake in shares of Kiniksa Pharmaceuticals by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock valued at $27,000 after purchasing an additional 568 shares during the period. Asset Management One Co. Ltd. purchased a new position in Kiniksa Pharmaceuticals in the 1st quarter valued at about $41,000. Wealthquest Corp acquired a new stake in shares of Kiniksa Pharmaceuticals during the first quarter valued at about $42,000. Lazard Asset Management LLC purchased a new stake in shares of Kiniksa Pharmaceuticals during the fourth quarter worth about $61,000. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Kiniksa Pharmaceuticals in the fourth quarter worth about $158,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.